Novo Nordisk A/S
Bear Case (25th pct.)
419.8% vs price
Base Case (Median)
811.4% vs price
Bull Case (75th pct.)
837.7% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $463.50 | 833.2% | High (40%) |
| PE Comparable | $610.25 | 1128.6% | Medium (25%) |
| Growth Trajectory DCF | $467.98 | 842.2% | Medium (20%) |
| Graham Number | $164.03 | 230.2% | Medium (40%) |
| EV/EBITDA | $352.37 | 609.4% | Medium (20%) |
| EV/FCF | $139.52 | 180.9% | Medium (20%) |
| Earnings Power Value | $452.70 | 811.4% | Medium (50%) |
Based on 7 out of 8 methods, NVO appears undervalued at the current price of $49.67. The base case fair value of $452.70 implies 811.4% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.